Skip to main
EPRX
EPRX logo

EPRX Stock Forecast & Price Target

EPRX Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eupraxia Pharmaceuticals Inc. benefits from a strengthened competitive position following the recent CLDX announcement, which eliminates a potential competitor in eosinophilic esophagitis (EoE) and reinforces the effectiveness of its product EP-104GI. Additionally, the successful outcomes from the Phase 1b/2a RESOLVE study, showcasing durability in drug release and improved treatment results, provide a strong foundation for the company's therapeutic viability. Management anticipates that positive Phase 2b results could lead to the initiation of a pivotal Phase 3 trial in early 2027, further bolstering the prospects for regulatory approval and market entry.

Bears say

Eupraxia Pharmaceuticals faces significant challenges due to potential risks associated with cross-border supply chains and tariffs, which could adversely affect its operational efficiency and cost structure. Such risks may impede the timely delivery of its products and limit market accessibility, leading to potential revenue losses. Additionally, the reliance on developing and commercializing its proprietary technology in a competitive biotechnology landscape raises further uncertainties regarding its financial stability and growth prospects.

EPRX has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eupraxia Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eupraxia Pharmaceuticals Inc (EPRX) Forecast

Analysts have given EPRX a Buy based on their latest research and market trends.

According to 2 analysts, EPRX has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eupraxia Pharmaceuticals Inc (EPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.